1
|
Sgherza N, Curci P, Brindicci G, Capozzi A, Di Carlo G, Grande D, Brescia V, Rossi AR, Musto P. Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study. Ann Hematol 2024:10.1007/s00277-024-05784-y. [PMID: 38702445 DOI: 10.1007/s00277-024-05784-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 04/27/2024] [Indexed: 05/06/2024]
Affiliation(s)
- Nicola Sgherza
- Hematology and Bone Marrow Transplantation Unit, AOU Policlinico Consorziale di Bari, Bari, Italy
| | - Paola Curci
- Hematology and Bone Marrow Transplantation Unit, AOU Policlinico Consorziale di Bari, Bari, Italy
| | - Gaetano Brindicci
- Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Alessandro Capozzi
- Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Gabriella Di Carlo
- Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Domenica Grande
- Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Vincenzo Brescia
- Clinical Pathology Unit, AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Bari, Italy
| | - Antonella Russo Rossi
- Hematology and Bone Marrow Transplantation Unit, AOU Policlinico Consorziale di Bari, Bari, Italy
| | - Pellegrino Musto
- Hematology and Bone Marrow Transplantation Unit, AOU Policlinico Consorziale di Bari, Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
- Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
| |
Collapse
|
2
|
Malagola M, Iurlo A, Bucelli C, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, De Gobbi M, Romano A, Tiribelli M, Russo Rossi A, Russo S, Defina M, Farina M, Bernardi S, Butturini G, Pellizzeri S, Roccaro AM, Russo D. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk 2024:S2152-2650(24)00035-1. [PMID: 38369436 DOI: 10.1016/j.clml.2024.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Revised: 01/15/2024] [Accepted: 01/15/2024] [Indexed: 02/20/2024]
Abstract
BACKGROUND Intermittent treatment with tyrosine kinase inhibitors (TKIs) is an option for elderly chronic myeloid leukemia (CML) patients who are often candidates for life-long treatment. MATERIALS AND METHODS The Italian phase III multicentric randomized Optimize TKIs Multiple Approaches (OPTkIMA) study aimed to evaluate if a progressive de-escalation of TKIs is able to maintain the molecular remission (MR)3.0 and to improve Health-Related Quality of Life (HRQoL) in CML elderly patients. RESULTS A total of 215 patients in stable MR3.0/MR4.0 were randomized to receive an intermittent TKI schedule 1 month ON-1 month OFF for 3 years (FIXED arm; n = 111) vs. a progressive de-escalation TKI dose up to one-third of the starting dose at the 3rd year (PROGRESSIVE arm; n = 104). Two hundred three patients completed the 3rd year of OPTkIMA study. At the last follow-up, MR3.0 loss was 27% vs. 46% (P = .005) in the FIXED vs PROGRESSIVE arm, respectively. None of these patients experienced disease progression. The 3-year probability of maintaining the MR3.0 was 59% vs. 53%, respectively (P = .13). HRQoL globally improved from the baseline to the 3rd year, without any significant difference between the 2 arms. After the 3rd year, the proportion of patients who was address to TKI discontinuation in the 2 arms was 36% (FIXED) vs. 58% (PROGRESSIVE) (P = .03). CONCLUSIONS The intensification of intermittent TKI therapy is associated with a higher incidence of MR3.0 loss, but those patients who maintain the MR3.0 molecular response at the end of the study have been frequently considered eligible for TFR. The HRQoL generally improved during the de-escalation therapy in both randomization arms.
Collapse
Affiliation(s)
- Michele Malagola
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy.
| | - Alessandra Iurlo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - Cristina Bucelli
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - Elisabetta Abruzzese
- Division of Hematology, S. Eugenio Hospital, ASL ROMA2, Tor Vergata University, Roma, Italy
| | - Massimiliano Bonifacio
- Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area - University of Verona, Italy
| | - Fabio Stagno
- Hematology Unit, AOU Policlinico "G. Martino", University of Messina, Italy
| | - Gianni Binotto
- Hematology and Clinical Immunology, Department of Medicine, Padua School of Medicine, Padova, Italy
| | - Marienlla D'Adda
- Division of Hematology, ASST-Spedali Civili di Brescia, Brescia, Italy
| | - Monia Lunghi
- Division of Hematology, Department of Translation Medicine, University of Eastern Piedmont, Novara, Italy
| | - Monica Crugnola
- Hematology Unit and BMT Center University Hospital of Parma, Italy
| | - Maria Luisa Ferrari
- Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - Francesca Lunghi
- Hematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute, Milano, Italy
| | - Fausto Castagnetti
- Institute of Hematology "Seràgnoli" IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy
| | - Gianantonio Rosti
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy
| | - Roberto Massimo Lemoli
- Chair of Hematology, Internal Medicine Dpt, University of Genova, Italy; Clinic of Hematology, IRCCS Policlinico San Martino, Genova, Italy
| | | | | | - Maria Teresa Corsetti
- Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - Marco De Gobbi
- Hematology and Internal Medicine Division, San Luigi Hospital, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
| | - Atelda Romano
- IRCCS Regina Elena National Cancer Institute-Roma, Italy
| | - Mario Tiribelli
- Division of Hematology and BMT, Department of Medicine, University of Udine, Udine, Italy
| | | | - Sabina Russo
- Division of Hematology, Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva, Policlinico G Martino, University of Messina, Messina, Italy
| | - Marzia Defina
- Hematology Unit, Dipartimento Terapie Cellulari, Ematologia e Medicina di Laboratorio, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
| | - Mirko Farina
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy
| | - Simona Bernardi
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy; CREA Laboratory (Hematological-Research AIL Centre), ASST-Spedali Civili Brescia, Italy
| | - Giulia Butturini
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy
| | - Simone Pellizzeri
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy
| | - Aldo Maria Roccaro
- Clinical Trial Center. Translational Research and Phase I Unit, ASST Spedali Civili, Brescia, Italy
| | - Domenico Russo
- Chair of Hematology, Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Disease and Stem Cell Transplantation, ASST-Spedali Civili, Brescia, Italy
| |
Collapse
|
3
|
Tarantini F, Cumbo C, Parciante E, Anelli L, Zagaria A, Coccaro N, Minervini CF, Tota G, Redavid I, Conserva MR, Attolico I, Rossi AR, Specchia G, Musto P, Albano F. IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective. Acta Haematol 2023; 146:37-43. [PMID: 36195064 DOI: 10.1159/000527173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 09/14/2022] [Indexed: 02/03/2023]
Abstract
INTRODUCTION Interferon regulatory factor 4 (IRF4) is a transcriptional factor with a key role in the modulation of inflammation and immune surveillance. The IRF4 gene is downregulated in Philadelphia-negative myeloproliferative neoplasms, and its expression is associated with prognosis and response to treatment. METHODS We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. RESULTS A relationship between the IRF4 expression and the disease burden was observed at various disease stages. A correlation analysis between the International Scale (IS) and IRF4 values confirmed this close association. A significant increase is detected after 3 months of TKI treatment. Patients achieving an early molecular response (EMR) had higher IRF4 values at both diagnosis and after 3 months of therapy as compared to those failing the EMR target. Patients achieving treatment-free remission did not show IRF4 fluctuations during monitoring, while a decreased IRF4 expression emerged at the time of molecular relapse. CONCLUSION Our data seem to confirm the relevance of IRF4 in the pathogenesis of CML, suggesting a pivotal role at the disease onset and a predictive value during the CML course.
Collapse
Affiliation(s)
- Francesco Tarantini
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Cosimo Cumbo
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Elisa Parciante
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Luisa Anelli
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Zagaria
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Nicoletta Coccaro
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Crescenzio Francesco Minervini
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Giuseppina Tota
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Immacolata Redavid
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Maria Rosa Conserva
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Immacolata Attolico
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Russo Rossi
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | | | - Pellegrino Musto
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| | - Francesco Albano
- Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari "Aldo Moro", Bari, Italy
| |
Collapse
|
4
|
Tarantini F, Cumbo C, Zagaria A, Anelli L, Parciante E, Redavid I, Coccaro N, Tota G, Conserva MR, Minervini CF, Minervini A, Attolico I, Russo Rossi A, Specchia G, Musto P, Albano F. Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event. Leuk Res 2023; 127:107023. [PMID: 36822077 DOI: 10.1016/j.leukres.2023.107023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 12/27/2022] [Accepted: 01/22/2023] [Indexed: 01/26/2023]
Abstract
Life expectation of chronic myeloid leukemia patients in the tyrosine kinase inhibitors era is almost equal to that of healthy subjects. On the other hand, their long-term management must take into account a higher risk of adverse events, at least partly related to the treatment. Various studies reported a higher incidence of cardiovascular events in these patients. Clonal hematopoiesis is broadly considered a major independent risk factor for cardiovascular events. Of note, the underlying physiopathological mechanisms connect clonal hematopoiesis with a global proinflammatory status, triggering a vicious circle in which the somatic mutations and inflammation feed each other. All this considered, we investigated the occurrence of clonal hematopoiesis in chronic myeloid leukemia patients developing a cardiovascular event under tyrosine kinase inhibitor therapy.
Collapse
Affiliation(s)
- Francesco Tarantini
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Cosimo Cumbo
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Antonella Zagaria
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Luisa Anelli
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Elisa Parciante
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Immacolata Redavid
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Nicoletta Coccaro
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Giuseppina Tota
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Maria Rosa Conserva
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Crescenzio Francesco Minervini
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Angela Minervini
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Immacolata Attolico
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Antonella Russo Rossi
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Giorgina Specchia
- School of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Pellegrino Musto
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy
| | - Francesco Albano
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell Transplantation Unit - University of Bari "Aldo Moro", 70124 Bari, Italy.
| |
Collapse
|
5
|
Galletti M, Alesini D, Anania MP, Arjmand S, Behtouei M, Bellaveglia M, Biagioni A, Buonomo B, Cardelli F, Carpanese M, Chiadroni E, Cianchi A, Costa G, Del Dotto A, Del Giorno M, Dipace F, Doria A, Filippi F, Franzini G, Giannessi L, Giribono A, Iovine P, Lollo V, Mostacci A, Nguyen F, Opromolla M, Pellegrino L, Petralia A, Petrillo V, Piersanti L, Di Pirro G, Pompili R, Romeo S, Rossi AR, Selce A, Shpakov V, Stella A, Vaccarezza C, Villa F, Zigler A, Ferrario M. Stable Operation of a Free-Electron Laser Driven by a Plasma Accelerator. Phys Rev Lett 2022; 129:234801. [PMID: 36563228 DOI: 10.1103/physrevlett.129.234801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Revised: 10/25/2022] [Accepted: 11/08/2022] [Indexed: 06/17/2023]
Abstract
The breakthrough provided by plasma-based accelerators enabled unprecedented accelerating fields by boosting electron beams to gigaelectronvolt energies within a few centimeters [1-4]. This, in turn, allows the realization of ultracompact light sources based on free-electron lasers (FELs) [5], as demonstrated by two pioneering experiments that reported the observation of self-amplified spontaneous emission (SASE) driven by plasma-accelerated beams [6,7]. However, the lack of stability and reproducibility due to the intrinsic nature of the SASE process (whose amplification starts from the shot noise of the electron beam) may hinder their effective implementation for user purposes. Here, we report a proof-of-principle experiment using plasma-accelerated beams to generate stable and reproducible FEL light seeded by an external laser. FEL radiation is emitted in the infrared range, showing the typical exponential growth of its energy over six consecutive undulators. Compared to SASE, the seeded FEL pulses have energies 2 orders of magnitude larger and stability that is 3 times higher.
Collapse
Affiliation(s)
- M Galletti
- Department of Physics, Università di Roma Tor Vergata, Via Ricerca Scientifica 1, 00133 Rome, Italy
- INFN-Tor Vergata, Via Ricerca Scientifica 1, 00133 Rome, Italy
- NAST Center, Via Ricerca Scientifica 1, 00133 Rome, Italy
| | - D Alesini
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - M P Anania
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - S Arjmand
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - M Behtouei
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - M Bellaveglia
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Biagioni
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - B Buonomo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - F Cardelli
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - M Carpanese
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
| | - E Chiadroni
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
- Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - A Cianchi
- Department of Physics, Università di Roma Tor Vergata, Via Ricerca Scientifica 1, 00133 Rome, Italy
- INFN-Tor Vergata, Via Ricerca Scientifica 1, 00133 Rome, Italy
- NAST Center, Via Ricerca Scientifica 1, 00133 Rome, Italy
| | - G Costa
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Del Dotto
- ENEA, C.R. Brasimone, 40032, Camugnano, Bologna, Italy
| | - M Del Giorno
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - F Dipace
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Doria
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
| | - F Filippi
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
| | - G Franzini
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - L Giannessi
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Giribono
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - P Iovine
- INFN-Napoli, Via Cintia, 80126 Naples, Italy
| | - V Lollo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Mostacci
- Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - F Nguyen
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
| | - M Opromolla
- Università degli Studi di Milano, Via Celoria 16 20133 Milano Italy
- INFN-Milano, Via Celoria 16, 20133 Milan, Italy
| | - L Pellegrino
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Petralia
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
| | - V Petrillo
- Università degli Studi di Milano, Via Celoria 16 20133 Milano Italy
- INFN-Milano, Via Celoria 16, 20133 Milan, Italy
| | - L Piersanti
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - G Di Pirro
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - R Pompili
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - S Romeo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A R Rossi
- INFN-Milano, Via Celoria 16, 20133 Milan, Italy
| | - A Selce
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, via Enrico Fermi 45, 00044 Frascati, Italy
- INFN-Roma Tre, Via della Vasca Navale 84, 00146 Roma RM, Italy
| | - V Shpakov
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Stella
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - C Vaccarezza
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - F Villa
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| | - A Zigler
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
- Racah Institute of Physics, Hebrew University, 91904 Jerusalem, Israel
| | - M Ferrario
- Laboratori Nazionali di Frascati, Via Enrico Fermi 54, 00044 Frascati, Italy
| |
Collapse
|
6
|
Tarantini F, Cumbo C, Zagaria A, Parciante E, Anelli L, Coccaro N, Tota G, Minervini CF, Redavid I, Rossi AR, Conserva MR, Specchia G, Musto P, Albano F. JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? Hematology 2022; 27:842-846. [PMID: 35938951 DOI: 10.1080/16078454.2022.2108902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios. METHODS BCR-ABL1 molecular monitoring was performed by real-time quantitative PCR (RQ-PCR). At the time of molecular relapse, a targeted next-generation sequencing analysis with a customized panel of 26 genes commonly mutated in myeloid diseases was performed. To investigate the kinetics of the JAK2 variant and its association with the BCR-ABL1 rearrangement, RQ-PCR was performed at different time points during the patient's follow-up. RESULTS While negative at CML diagnosis, the JAK2 mutation was first detected 9 years later (VAF: 7.2%). The mutational burden of JAK2 remained stable in multiple determinations, with minor fluctuations independent of BCR-ABL1 kinetics. At the last available time point, the patient was in deep molecular response (MR4), the JAK2 mutational burden was 7%, and no clinical-laboratory findings of Ph-MPN were detectable. DISCUSSION In the presented case, the JAK2variantoccurring during the course of the disease seems to stay in the shadows of CML, just as a bystander. The impact of this event (that may be considered suggestive of clonal hematopoiesis of indeterminate potential) on the disease outcome, even if seemingly irrelevant, has still to be explored.
Collapse
Affiliation(s)
- Francesco Tarantini
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Cosimo Cumbo
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Zagaria
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Elisa Parciante
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Luisa Anelli
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Nicoletta Coccaro
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Giuseppina Tota
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Crescenzio Francesco Minervini
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Immacolata Redavid
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Russo Rossi
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Maria Rosa Conserva
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | | | - Pellegrino Musto
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Francesco Albano
- Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| |
Collapse
|
7
|
Pompili R, Alesini D, Anania MP, Arjmand S, Behtouei M, Bellaveglia M, Biagioni A, Buonomo B, Cardelli F, Carpanese M, Chiadroni E, Cianchi A, Costa G, Del Dotto A, Del Giorno M, Dipace F, Doria A, Filippi F, Galletti M, Giannessi L, Giribono A, Iovine P, Lollo V, Mostacci A, Nguyen F, Opromolla M, Di Palma E, Pellegrino L, Petralia A, Petrillo V, Piersanti L, Di Pirro G, Romeo S, Rossi AR, Scifo J, Selce A, Shpakov V, Stella A, Vaccarezza C, Villa F, Zigler A, Ferrario M. Free-electron lasing with compact beam-driven plasma wakefield accelerator. Nature 2022; 605:659-662. [PMID: 35614244 DOI: 10.1038/s41586-022-04589-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 02/25/2022] [Indexed: 11/09/2022]
Abstract
The possibility to accelerate electron beams to ultra-relativistic velocities over short distances by using plasma-based technology holds the potential for a revolution in the field of particle accelerators1-4. The compact nature of plasma-based accelerators would allow the realization of table-top machines capable of driving a free-electron laser (FEL)5, a formidable tool to investigate matter at the sub-atomic level by generating coherent light pulses with sub-ångström wavelengths and sub-femtosecond durations6,7. So far, however, the high-energy electron beams required to operate FELs had to be obtained through the use of conventional large-size radio-frequency (RF) accelerators, bound to a sizeable footprint as a result of their limited accelerating fields. Here we report the experimental evidence of FEL lasing by a compact (3-cm) particle-beam-driven plasma accelerator. The accelerated beams are completely characterized in the six-dimensional phase space and have high quality, comparable with state-of-the-art accelerators8. This allowed the observation of narrow-band amplified radiation in the infrared range with typical exponential growth of its intensity over six consecutive undulators. This proof-of-principle experiment represents a fundamental milestone in the use of plasma-based accelerators, contributing to the development of next-generation compact facilities for user-oriented applications9.
Collapse
Affiliation(s)
- R Pompili
- Laboratori Nazionali di Frascati, Frascati, Italy.
| | - D Alesini
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - M P Anania
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - S Arjmand
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - M Behtouei
- Laboratori Nazionali di Frascati, Frascati, Italy
| | | | - A Biagioni
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - B Buonomo
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - F Cardelli
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - M Carpanese
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | - E Chiadroni
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Cianchi
- University of Rome Tor Vergata, Rome, Italy.,INFN Tor Vergata, Rome, Italy.,NAST Center, Rome, Italy
| | - G Costa
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Del Dotto
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - M Del Giorno
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - F Dipace
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Doria
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | - F Filippi
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | - M Galletti
- University of Rome Tor Vergata, Rome, Italy.,INFN Tor Vergata, Rome, Italy.,NAST Center, Rome, Italy
| | - L Giannessi
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Giribono
- Laboratori Nazionali di Frascati, Frascati, Italy
| | | | - V Lollo
- Laboratori Nazionali di Frascati, Frascati, Italy
| | | | - F Nguyen
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | | | - E Di Palma
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | - L Pellegrino
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Petralia
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | | | - L Piersanti
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - G Di Pirro
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - S Romeo
- Laboratori Nazionali di Frascati, Frascati, Italy
| | | | - J Scifo
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Selce
- ENEA Fusion and Technology for Nuclear Safety and Security Department (FSN), C.R. Frascati, Frascati, Italy
| | - V Shpakov
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Stella
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - C Vaccarezza
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - F Villa
- Laboratori Nazionali di Frascati, Frascati, Italy
| | - A Zigler
- Laboratori Nazionali di Frascati, Frascati, Italy.,Racah Institute of Physics, Hebrew University, Jerusalem, Israel
| | - M Ferrario
- Laboratori Nazionali di Frascati, Frascati, Italy
| |
Collapse
|
8
|
Cumbo C, Tarantini F, Zagaria A, Anelli L, Minervini CF, Coccaro N, Tota G, Impera L, Parciante E, Conserva MR, Redavid I, Carluccio P, Delia M, Giordano A, Longo MC, Perrone T, Rossi AR, Specchia G, Musto P, Albano F. Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? Front Oncol 2022; 12:873896. [PMID: 35494055 PMCID: PMC9039212 DOI: 10.3389/fonc.2022.873896] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 03/21/2022] [Indexed: 12/23/2022] Open
Abstract
Inflammatory bowel diseases (IBDs) are a group of chronic conditions of the gastrointestinal tract in which nationwide studies have revealed a higher risk of hematological malignancies (HMs). Clonal hematopoiesis (CH) is a premalignant condition defined by the presence of an acquired somatic mutation characterized by a variant allele frequency (VAF) of ≥2%, in a gene frequently associated with HMs. A growing body of evidence suggests a correlation between inflammation and CH; its occurrence in the context of IBD has been previously demonstrated. With the aim to assess CH possible co-occurrence in patients with an IBD associated with HMs, we performed a targeted next-generation sequencing analysis in a cohort of thirteen patients who were referred to our center with IBD associated with HMs. Eleven (85%) patients showed one or more mutations in CH-associated genes; DNMT3A was the most frequently mutated gene, followed by ASXL1 and JAK2. These results may suggest that the mechanisms at the basis of the inflammatory environment could potentially select for the growth of hematopoietic clones harboring specific mutations. In this context, CH emergence may be boosted by the proinflammatory IBD environment, thus acting as a biological link between IBD and the HM onset. If these data are confirmed, IBD patients screened and positive for CH should undergo a hematologic follow-up to assess the risk of developing HM. Future study will clarify the relationship between these conditions.
Collapse
Affiliation(s)
- Cosimo Cumbo
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Francesco Tarantini
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Zagaria
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Luisa Anelli
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Crescenzio Francesco Minervini
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Nicoletta Coccaro
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Giuseppina Tota
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Luciana Impera
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Elisa Parciante
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Maria Rosa Conserva
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Immacolata Redavid
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Paola Carluccio
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Mario Delia
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Annamaria Giordano
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Maria Chiara Longo
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Tommasina Perrone
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Russo Rossi
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | | | - Pellegrino Musto
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| | - Francesco Albano
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy
| |
Collapse
|
9
|
Sicuranza A, Ferrigno I, Abruzzese E, Iurlo A, Galimberti S, Gozzini A, Luciano L, Stagno F, Russo Rossi A, Sgherza N, Cattaneo D, Zuanelli Brambilla C, Marzano C, Fava C, Mulas O, Cencini E, Santoni A, Sammartano V, Gozzetti A, Puccetti L, Bocchia M. Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Front Oncol 2022; 12:835563. [PMID: 35178353 PMCID: PMC8844441 DOI: 10.3389/fonc.2022.835563] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 01/10/2022] [Indexed: 11/13/2022] Open
Abstract
Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, a higher than expected incidence of arterial occlusive events (AOEs) was observed during treatment with nilotinib. We previously showed an “inflammatory status” during nilotinib that may explain the increased incidence of AOEs. Thus, we conducted this prospective KIARO study involving 186 CML patients (89 imatinib, 59 nilotinib, 38 dasatinib). Interleukin 6 (IL6), interleukin 10 (IL10), Tumor Necrosis Factor-α (TNFα), oxLDL, and high-sensitivity C-reactive protein (hs-CRP) plasma levels were measured at diagnosis and during treatment, with the aim to investigate changes in the inflammatory status favoring AOEs of each patient. Clinical and biochemical pro-atherothrombotic profiles and the 10-year SCORE chart were also evaluated. We showed a pro-inflammatory/pro-oxidative milieu increasing along treatment with nilotinib compared with imatinib or dasatinib, as demonstrated by higher hs-CRP and oxLDL levels and increased IL6/IL10 and TNFα/IL10 ratios only in nilotinib cohort. After median follow-up of 23.3 months starting from TKI, 10/186 patients (5.4%) suffered an AOE. Approximately 5/10 (50%) AOEs occurred during nilotinib treatment despite a lower 10-year SCORE and a lower median age in this subgroup. A longer follow-up is needed to further confirm the active role of nilotinib in AOEs pathogenesis.
Collapse
Affiliation(s)
- Anna Sicuranza
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Ilaria Ferrigno
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | | | - Alessandra Iurlo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Sara Galimberti
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Antonella Gozzini
- Department of Cellular Therapies and Transfusion Medicine, AOU Careggi, Florence, Italy
| | | | - Fabio Stagno
- Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico-V. Emanuele, Catania, Italy
| | | | - Nicola Sgherza
- Hematology and Transplant Center, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
| | - Daniele Cattaneo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Cristina Marzano
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Carmen Fava
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - Olga Mulas
- Department of Medical Sciences and Public Health, University of Cagliari, Businco Hospital, Cagliari, Italy
| | - Emanuele Cencini
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Adele Santoni
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Vincenzo Sammartano
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Alessandro Gozzetti
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Luca Puccetti
- Hemostasis and Thrombosis Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| | - Monica Bocchia
- Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy
| |
Collapse
|
10
|
Stagno F, Breccia M, Annunziata M, Trawinska MM, Iurlo A, Sgherza N, Fava C, Gozzini A, Luciano L, Carmosino I, Bonifacio M, Sorà F, Leonetti Crescenzi S, Crugnola M, Gugliotta G, Galimberti S, Bucelli C, Colafigli G, Feo C, Tiribelli M, Mauro E, Russo Rossi A, Guarini A, Abruzzese E, Rosti G, Di Raimondo F, Latagliata R. Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta Oncol 2021; 60:1527-1533. [PMID: 34499575 DOI: 10.1080/0284186x.2021.1971292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND A limited amount of data has been published in chronic-phase chronic myeloid leukemia (CP-CML) patients aged >75 years treated frontline with second-generation tyrosine kinase inhibitors. AIMS To address this issue in a clinical 'real-life' setting, we retrospectively analyzed 45 CP-CML patients (pts) followed in 20 Italian Centers and treated frontline with dasatinib (DAS). PATIENTS AND METHODS Median age was 78.4 years (range 75-89.2 years). DAS starting dose was 100 mg QD in 35 pts (77.7%), 80 mg QD in 1 pts (2.2%) and 50 mg QD in 9 pts (20.1%), respectively. The median follow-up was 42.6 months (IQR 20.4 - 63.3). RESULTS Grade 3 and 4 side effects, both hematological and non-hematological, were detected in 6 (13.3%) and 12 (26.6%) pts, respectively. Pleural effusions of all grades occurred in 13 pts (28.8%) after a median period of DAS exposure of 14.7 months (IQR 3.0 - 33.1). The rates of DAS dose reduction and permanent drug discontinuation were 53.3% and 20.0%, respectively. As the best response, 42/45 patients (93.3%) achieved a complete cytogenetic response (CCyR), 35/45 (77.7%) a major molecular response (MMR) and 24/45 (53.3%) a deep molecular response (both MR 4.0 and MR 4.5). Only 1 patient (2.2%) progressed to the blast phase after 13 months of therapy; 8 deaths were observed (1 CML-related and 7 CML-unrelated). Cumulative event-free survival and overall survival at 36 months were 64.7% (95%, CI 49.4 - 80.0) and 82.3% (95%, CI 70.3-94.3), respectively. CONCLUSION These findings, although evaluated in a limited and selected cohort of patients, suggest that DAS might be effective in older patients (aged >75 years) affected by CP-CML with acceptable toxicity.
Collapse
Affiliation(s)
- Fabio Stagno
- Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico Rodolico-San Marco, Catania, Italy
| | - Massimo Breccia
- Department of Precision and Translational Medicine, Sapienza University, Rome, Italy
| | | | | | - Alessandra Iurlo
- Hematology Section, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Nicola Sgherza
- Hematology Unit, IRCCS “Casa Sollievo Sofferenza” Hospital, San Giovanni Rotondo, Italy
| | - Carmen Fava
- Hematology Section, Azienda Ospedaliera Mauriziano, Turin, Italy
| | | | | | - Ida Carmosino
- Department of Precision and Translational Medicine, Sapienza University, Rome, Italy
| | | | - Federica Sorà
- Hematology Section, Policlinico A. Gemelli, IRCSS Catholic University, Rome, Italy
| | | | | | - Gabriele Gugliotta
- Hematology Section “Seragnoli”, IRCCS AOU Bologna, University of Bologna, Bologna, Italy
| | | | - Cristina Bucelli
- Hematology Section, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Gioia Colafigli
- Department of Precision and Translational Medicine, Sapienza University, Rome, Italy
| | - Costanzo Feo
- Immunohematology and Transfusion Unit, AORN “Gaetano Rummo”, Benevento, Italy
| | - Mario Tiribelli
- Hematology Section and BMT, University of Udine, Udine, Italy
| | - Endri Mauro
- Hematology Section, Dipartimento di Medicina Specialistica, Ca’ Foncello Hospital, Treviso, Italy
| | | | - Attilio Guarini
- Unit of Hematology and Cell Therapy, IRCCS-Istituto Tumori “Giovanni Paolo II”, Bari, Italy
| | | | | | - Francesco Di Raimondo
- Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico Rodolico-San Marco, Catania, Italy
| | | |
Collapse
|
11
|
Attolico I, Tarantini F, Carluccio P, Schifone CP, Delia M, Gagliardi VP, Perrone T, Gaudio F, Longo C, Giordano A, Sgherza N, Curci P, Rizzi R, Ricco A, Russo Rossi A, Albano F, Larocca AMV, Vimercati L, Tafuri S, Musto P. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. Br J Haematol 2021; 196:928-931. [PMID: 34664267 PMCID: PMC8652694 DOI: 10.1111/bjh.17873] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Immacolata Attolico
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Francesco Tarantini
- Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Paola Carluccio
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Claudia Pia Schifone
- Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Mario Delia
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Vito Pier Gagliardi
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Tommasina Perrone
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Francesco Gaudio
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Chiara Longo
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Annamaria Giordano
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Nicola Sgherza
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Paola Curci
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | - Rita Rizzi
- Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy
| | - Alessandra Ricco
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
| | | | - Francesco Albano
- Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy
| | | | - Luigi Vimercati
- Interdisciplinary Department of Medicine, "Aldo Moro" University School of Medicine, Bari, Italy.,Occupational Medicine Unit, AOUC Policlinico, Bari, Italy
| | - Silvio Tafuri
- Department of Biomedical Sciences and Human Oncology, 'Aldo Moro' University School of Medicine, Bari, Italy
| | - Pellegrino Musto
- Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy.,Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy
| |
Collapse
|
12
|
Malagola M, Iurlo A, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, Rege Cambrin G, Romano A, Tiribelli M, Russo Rossi A, Russo S, Aprile L, Bocchia M, Gandolfi L, Farina M, Bernardi S, Polverelli N, Roccaro AM, De Vivo A, Baccarani M, Russo D. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Med 2021; 10:1726-1737. [PMID: 33594821 PMCID: PMC7940223 DOI: 10.1002/cam4.3778] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 10/15/2020] [Accepted: 01/20/2021] [Indexed: 12/12/2022] Open
Abstract
Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong. Methods The Italian phase III multicentric randomized OPTkIMA study started in 2015, with the aim to evaluate if a progressive de‐escalation of TKIs (imatinib, nilotinib, and dasatinib) is able to maintain the molecular response (MR3.0) and to improve Health Related Quality of Life (HRQoL). Results Up to December 2018, 166/185 (90%) elderly CML patients in stable MR3.0/MR4.0 completed the first year of any TKI intermittent schedule 1 month ON and 1 month OFF. The first year probability of maintaining the MR3.0 was 81% and 23.5% of the patients who lost the molecular response regained the MR3.0 after resuming TKI continuously. Patients’ HRQoL at baseline was better than that of matched peers from healthy population. Women was the only factor independently associated with worse baseline HRQoL (p > 0.0001). Overall, global HRQoL worsened at 6 (p < 0.001) but returned to the baseline value at 12 months and it was statistically significantly worse in women (p = 0.001). Conclusions De‐escalation of any TKI by 1 month ON/OFF schedule maintains the MR3.0/MR4.0 in 81% of the patients during the first 12–24 months. No patients progressed to accelerated/blastic phase, all the patients (23.5%) losing MR3.0 regained the MR3.0 and none suffered from TKI withdrawn syndrome. The study firstly report on HRQoL in elderly CML patients moving from a continuous daily therapy to a de‐escalated intermittent treatment.
Collapse
Affiliation(s)
- Michele Malagola
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy
| | - Alessandra Iurlo
- Hematology Division, Foundation IRCCS Ca, Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Elisabetta Abruzzese
- Division of Hematology, S. Eugenio Hospital, ASL ROMA2, Tor Vergata University, Roma, Italy
| | | | - Fabio Stagno
- Department of Hematology, University of Catania, Catania, Italy
| | - Gianni Binotto
- Hematology and Clinical Immunology, Department of Medicine, Padua School of Medicine, Padua, Italy
| | - Mariella D'Adda
- Division of Hematology, ASST-Spedali Civili di Brescia, Brescia, Italy
| | - Monia Lunghi
- Division of Hematology, Department of Translation Medicine, University of Eastern Piedmont, Novara, Italy
| | - Monica Crugnola
- Hematology Unit and BMT Center Azienda Ospedaliero Universitaria Parma, Parma, Italy
| | - Maria Luisa Ferrari
- Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - Francesca Lunghi
- Hematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute, Milan, Italy
| | - Fausto Castagnetti
- Hematology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy
| | - Gianantonio Rosti
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Roberto M Lemoli
- Clinic of Hematology, University of Genoa, Ospedale Policlinico S. Martino, IRCCS, Genoa, Italy
| | | | | | - Maria Teresa Corsetti
- Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | | | - Atelda Romano
- IRCCS Regina Elena National Cancer Institute-Rome, Roma, Italy
| | - Mario Tiribelli
- Division of Hematology and BMT, Department of Medical and Morphological Researches, University of Udine, Udine, Italy
| | | | - Sabina Russo
- Division of Hematology, Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva, Policlinico G Martino, University of Messina, Messina, Italy
| | - Lara Aprile
- SC Ematologia, Ospedale S.G.Moscati, Taranto, Italy
| | - Monica Bocchia
- Hematology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
| | - Lisa Gandolfi
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy
| | - Mirko Farina
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy
| | - Simona Bernardi
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy.,CREA Laboratory (Hematological-Research AIL Centre), ASST-Spedali Civili Brescia, Brescia, Italy
| | - Nicola Polverelli
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy
| | - Aldo M Roccaro
- Clinical Research Development and Phase I Unit, ASST-Spedali Civili Brescia, Brescia, Italy
| | - Antonio De Vivo
- Hematology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy
| | | | - Domenico Russo
- Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spedali Civili, Brescia, Italy
| |
Collapse
|
13
|
Tarantini F, Anelli L, Ingravallo G, Attolico I, Zagaria A, Russo Rossi A, Lospalluti L, Bufano T, Zanframundo G, Maiorano E, Specchia G, Albano F. Skin lesions in chronic myeloid leukemia patients during dasatinib treatment. Cancer Manag Res 2019; 11:7991-7996. [PMID: 31692557 PMCID: PMC6717053 DOI: 10.2147/cmar.s217872] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Accepted: 07/26/2019] [Indexed: 12/30/2022] Open
Abstract
Purpose In our work we sought to define the prevalence rates of cutaneous events during dasatinib therapy in chronic myeloid leukemia (CML) patients and to investigate the clinical and pathological characteristics of these reactions. Patients and methods In our institution, 67 CML patients were treated with dasatinib. it was given as first line treatment in 26 (39%) and subsequent treatment in 41 (61%) CML patients. Flow cytometry analysis of peripheral blood and cutaneous biopsy was done on all CML patients with dermatological lesions appearing during dasatinib treatment. Results Among 67 CML patients, 4 (5.9%) showed skin lesions during dasatinib treatment. The cutaneous manifestations were not generalized but mainly located on the back, abdomen, thorax or leg regions. The patients did not show peripheral lymphocytosis at the time when skin lesions appeared. Overall, histological analysis showed that the skin lesions were characterized by a mild perivascular small CD8+ T lymphocytes infiltrate with minimal epidermotropism. Conclusion The unusual T cytotoxic cutaneous infiltrate demonstrated in our CML cases could be the expression of a dasatinib-promoted lymphocyte expansion. However, the heterogeneity of the dermatologic manifestations reported in our CML patients could also be related to unknown factors specific to each CML patient. Our work highlights the finding that skin lesions may be associated with dasatinib treatment and that they should not be confused with viral or bacterial infections but rather interpreted as the clinical expression of lymphocytosis promoted by this TKI.
Collapse
Affiliation(s)
- Francesco Tarantini
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Luisa Anelli
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Giuseppe Ingravallo
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Immacolata Attolico
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Zagaria
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Antonella Russo Rossi
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Lucia Lospalluti
- Department of Biomedical Sciences and Clinical Oncology, Dermatology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Tamara Bufano
- Department of Biomedical Sciences and Clinical Oncology, Dermatology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Giovanni Zanframundo
- Department of Biomedical Sciences and Clinical Oncology, Dermatology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Eugenio Maiorano
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Giorgina Specchia
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| | - Francesco Albano
- Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari "Aldo Moro", Bari, Italy
| |
Collapse
|
14
|
Pompili R, Anania MP, Bellaveglia M, Biagioni A, Bini S, Bisesto F, Brentegani E, Cardelli F, Castorina G, Chiadroni E, Cianchi A, Coiro O, Costa G, Croia M, Di Giovenale D, Ferrario M, Filippi F, Giribono A, Lollo V, Marocchino A, Marongiu M, Martinelli V, Mostacci A, Pellegrini D, Piersanti L, Di Pirro G, Romeo S, Rossi AR, Scifo J, Shpakov V, Stella A, Vaccarezza C, Villa F, Zigler A. Focusing of High-Brightness Electron Beams with Active-Plasma Lenses. Phys Rev Lett 2018; 121:174801. [PMID: 30411933 DOI: 10.1103/physrevlett.121.174801] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Indexed: 06/08/2023]
Abstract
Plasma-based technology promises a tremendous reduction in size of accelerators used for research, medical, and industrial applications, making it possible to develop tabletop machines accessible for a broader scientific community. By overcoming current limits of conventional accelerators and pushing particles to larger and larger energies, the availability of strong and tunable focusing optics is mandatory also because plasma-accelerated beams usually have large angular divergences. In this regard, active-plasma lenses represent a compact and affordable tool to generate radially symmetric magnetic fields several orders of magnitude larger than conventional quadrupoles and solenoids. However, it has been recently proved that the focusing can be highly nonlinear and induce a dramatic emittance growth. Here, we present experimental results showing how these nonlinearities can be minimized and lensing improved. These achievements represent a major breakthrough toward the miniaturization of next-generation focusing devices.
Collapse
Affiliation(s)
- R Pompili
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - M P Anania
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - M Bellaveglia
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Biagioni
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - S Bini
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - F Bisesto
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - E Brentegani
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - F Cardelli
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - G Castorina
- Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - E Chiadroni
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Cianchi
- University or Rome Tor Vergata and INFN, Via Ricerca Scientifica 1, 00133 Rome, Italy
| | - O Coiro
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - G Costa
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - M Croia
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - D Di Giovenale
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - M Ferrario
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - F Filippi
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Giribono
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - V Lollo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Marocchino
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - M Marongiu
- Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - V Martinelli
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Mostacci
- Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - D Pellegrini
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - L Piersanti
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - G Di Pirro
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - S Romeo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A R Rossi
- INFN Milano, via Celoria 16, 20133 Milan, Italy
| | - J Scifo
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - V Shpakov
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Stella
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - C Vaccarezza
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - F Villa
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
| | - A Zigler
- Laboratori Nazionali di Frascati, Via Enrico Fermi 40, 00044 Frascati, Italy
- Racah Institute of Physics, Hebrew University, 91904 Jerusalem, Israel
| |
Collapse
|
15
|
Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. Am J Hematol 2018; 93:E159-E161. [PMID: 29633312 DOI: 10.1002/ajh.25102] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2018] [Revised: 03/27/2018] [Accepted: 03/29/2018] [Indexed: 11/09/2022]
Affiliation(s)
- Giovanni Caocci
- Department of Medical Sciences and Public Health; University of Cagliari; Cagliari
| | - Olga Mulas
- Businco Hospital; Hematology and Transplant Center; Cagliari
| | | | | | | | - Ester Maria Orlandi
- Hematology Unit, “Fondazione IRCCS Policlinico S. Matteo” University Hospital; Pavia
| | - Patrizia Pregno
- Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza; Torino
| | - Sara Galimberti
- Department of Clinical and Experimental Medicine; Section of Hematology, University of Pisa; Pisa
| | | | | | - Alessandra Iurlo
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milano
| | - Bruno Martino
- Hematology Unit, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”; Reggio Calabria
| | - Nicola Sgherza
- Casa Sollievo della Sofferenza Hospital; Hematology and Transplant Center; San Giovanni Rotondo
| | | | - Fausto Castagnetti
- Department of Experimental, Diagnostic and Specialty Medicine; S. Orsola-Malpighi Hospital, University of Bologna; Bologna
| | | | - Claudio Fozza
- Department of Clinical and Experimental Medicine; University of Sassari; Sassari
| | - Monica Bocchia
- Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena; Siena
| | - Anna Sicuranza
- Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena; Siena
| | | | - Fabio Efficace
- Italian Group for Adult Hematologic Diseases (GIMEMA); Data Center and Health Outcomes Research Unit; Rome
| | - Emilio Usala
- Businco Hospital; Hematology and Transplant Center; Cagliari
| | | | - Luigi Scaffidi
- Department of Medicine; Section of Hematology, University of Verona; Verona
| | - Chiara Elena
- Hematology Unit, “Fondazione IRCCS Policlinico S. Matteo” University Hospital; Pavia
| | - Francesca Pirillo
- Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza; Torino
| | - Claudia Baratè
- Department of Clinical and Experimental Medicine; Section of Hematology, University of Pisa; Pisa
| | | | - Daniele Cattaneo
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milano
| | - Claudia Labate
- Hematology Unit, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”; Reggio Calabria
| | - Gabriele Gugliotta
- Department of Experimental, Diagnostic and Specialty Medicine; S. Orsola-Malpighi Hospital, University of Bologna; Bologna
| | - Matteo Molica
- Division of Hematology, Department of Cellular Biotechnologies and Hematology; Policlinico Umberto I, Sapienza University; Rome Italy
| | | | - Giorgio La Nasa
- Department of Medical Sciences and Public Health; University of Cagliari; Cagliari
| | - Robin Foà
- Division of Hematology, Department of Cellular Biotechnologies and Hematology; Policlinico Umberto I, Sapienza University; Rome Italy
| | - Massimo Breccia
- Division of Hematology, Department of Cellular Biotechnologies and Hematology; Policlinico Umberto I, Sapienza University; Rome Italy
| |
Collapse
|
16
|
Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 2018; 7:80083-80090. [PMID: 27579540 PMCID: PMC5346773 DOI: 10.18632/oncotarget.11657] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 07/13/2016] [Indexed: 11/25/2022] Open
Abstract
Background About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or not in imatinib-treated patients aged >75 years the exposure to polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response rates, event-free and overall survival, as well as on hematological or extra-hematological toxicity. Methods 296 patients at 35 Italian hematological institutions were evaluated. Results Polypharmacy was reported in 107 patients (36.1%), and drugs more frequently used were antiplatelets, diuretics, proton pump inhibitors, ACE-inhibitors, beta-blockers, calcium channel blockers, angiotensin II receptors blockers, statins, oral hypoglycemic drugs and alpha blockers. Complete cytogenetic response was obtained in 174 patients (58.8%), 78 (26.4%) within 6 month, 63 (21.3%) between 7 and 12 months. Major molecular response was obtained in 153 patients (51.7%), 64 (21.6%) within the 12 month. One hundred and twenty-eight cases (43.2%) of hematological toxicity were recorded, together with 167 cases (56.4%) of extra-hematological toxicity. Comparing patients exposed to polypharmacy to those without, no difference was observed pertaining to the dosage of imatinib, cytogenetic and molecular responses and hematological and extra-hematological toxicity. Conclusion Notwithstanding the several interactions reported in the literature between imatinib and some of the medications considered herewith, this fact does not seem to have a clinical impact on response rate and outcome.
Collapse
Affiliation(s)
- Alessandra Iurlo
- Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy
| | - Alessandro Nobili
- Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy
| | - Roberto Latagliata
- Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy
| | - Cristina Bucelli
- Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy
| | - Fausto Castagnetti
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Bologna, Italy
| | - Massimo Breccia
- Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy
| | | | - Daniele Cattaneo
- Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy
| | - Carmen Fava
- Division of Hematology and Internal Medicine, University of Turin, "San Luigi Gonzaga" University Hospital, Orbassano, Turin, Italy
| | | | | | | | - Mario Tiribelli
- Division of Hematology and BMT, Azienda Ospedaliero - Universitaria di Udine, Udine, Italy
| | - Patrizia Pregno
- Hematology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy
| | - Fabio Stagno
- Hematology Unit, Ferrarotto Hospital, Catania, Italy
| | - Paolo Vigneri
- Hematology Unit, Ferrarotto Hospital, Catania, Italy
| | | | | | | | - Giovanna Mansueto
- Department of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Italy
| | | | - Franca Falzetti
- Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy
| | | | - Gabriele Gugliotta
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Bologna, Italy
| | - Sergio Storti
- Onco-Hematology Unit, Università Cattolica Giovanni Paolo II, Campobasso, Italy
| | - Ada M D'Addosio
- Immunohematology and Trasfusional Medicine Division, S. Pietro Fatebenefratelli Hospital, Rome, Italy
| | - Luigi Scaffidi
- Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
| | - Laura Cortesi
- Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy
| | | | | | - Paolo Avanzini
- Hematology, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
| | - Endri Mauro
- Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy
| | - Antonio Spadea
- Hematology and Stem Cell Transplantation Unit, Regina Elena Institute, Rome, Italy
| | | | | | | | - Monica Crugnola
- Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
| | | | - Federica Sorà
- Institute of Hematology, Università Cattolica Sacro Cuore, Rome, Italy
| | - Giovanna Rege-Cambrin
- Division of Hematology and Internal Medicine, University of Turin, "San Luigi Gonzaga" University Hospital, Orbassano, Turin, Italy
| | - Simona Sica
- Institute of Hematology, Università Cattolica Sacro Cuore, Rome, Italy
| | - Luigiana Luciano
- Hematology Unit, ''Federico II'' Hospital, University of Naples, Naples, Italy
| | - Sara Galimberti
- Department of Clinical and Experimental Medicine, Section of Hematology - University of Pisa, Pisa, Italy
| | - Ester M Orlandi
- Oncology-Hematology Department, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Monica Bocchia
- Hematology Unit, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy
| | - Mauro Tettamanti
- Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy
| | - Giuliana Alimena
- Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy
| | - Giuseppe Saglio
- Division of Hematology and Internal Medicine, University of Turin, "San Luigi Gonzaga" University Hospital, Orbassano, Turin, Italy
| | - Gianantonio Rosti
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Bologna, Italy
| | - Pier Mannuccio Mannucci
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation and University of Milan, Milan, Italy
| | - Agostino Cortelezzi
- Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, University of Milan, Milan, Italy
| |
Collapse
|
17
|
Cumbo C, Impera L, Minervini CF, Orsini P, Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P, Brunetti C, Rossi AR, Parciante E, Specchia G, Albano F. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. Oncotarget 2018. [PMID: 29541390 PMCID: PMC5834283 DOI: 10.18632/oncotarget.23971] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended method is quantitative RT-PCR (RT-qPCR) for measuring BCR-ABL1 transcripts. Several studies reported that a DNA-based assay enhances the sensitivity of detection of the BCR-ABL1 genomic rearrangement, even if its characterization results difficult. We developed a DNA-based method for detecting and quantifying residual BCR-ABL1 positive leukemic stem cells in CML patients. We propose two alternative approaches: the first one is a fluorescence in situ hybridization (FISH)-based step followed by Sanger sequencing; the second one employs MinION, a single molecule sequencer based on nanopore technology. Finally, after defining the BCR-ABL1 genomic junction, we performed the target CML patient–specific quantification, using droplet digital PCR (ddPCR). FISH and MinION steps, respectively, together with ddPCR analysis, greatly reduce the complexity that has impeded the use of “personalized monitoring” of CML in clinical practice. Our report suggests a feasible pipeline, in terms of costs and reproducibility, aimed at characterizing and quantifying the genomic BCR-ABL1 rearrangement during MRD monitoring in CML patients.
Collapse
Affiliation(s)
- Cosimo Cumbo
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Luciana Impera
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | | | - Paola Orsini
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Luisa Anelli
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Antonella Zagaria
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Nicoletta Coccaro
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Giuseppina Tota
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Angela Minervini
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Paola Casieri
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Claudia Brunetti
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Antonella Russo Rossi
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Elisa Parciante
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Giorgina Specchia
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| | - Francesco Albano
- Department of Emergency and Organ Transplantation, Hematology Section, University of Bari, 70124 Bari, Italy
| |
Collapse
|
18
|
Delia M, Pastore D, Carluccio P, Pasciolla C, Ricco A, Rossi AR, Casieri P, Mestice A, Albano F, Specchia G. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. Clinical Lymphoma Myeloma and Leukemia 2017; 17:767-773. [DOI: 10.1016/j.clml.2017.06.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Revised: 06/09/2017] [Accepted: 06/09/2017] [Indexed: 12/19/2022]
|
19
|
Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia 2017; 18:536-40. [PMID: 27659013 PMCID: PMC5031865 DOI: 10.1016/j.neo.2016.07.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Revised: 07/19/2016] [Accepted: 07/25/2016] [Indexed: 12/02/2022] Open
Abstract
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Chromosome Banding
- Cohort Studies
- Dasatinib/administration & dosage
- Dasatinib/adverse effects
- Dasatinib/therapeutic use
- Follow-Up Studies
- Fusion Proteins, bcr-abl/genetics
- Humans
- In Situ Hybridization, Fluorescence
- Kaplan-Meier Estimate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Neoplasm Grading
- Protein Kinase Inhibitors/administration & dosage
- Protein Kinase Inhibitors/adverse effects
- Protein Kinase Inhibitors/therapeutic use
- Treatment Outcome
Collapse
Affiliation(s)
- Roberto Latagliata
- Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome.
| | - Fabio Stagno
- Chair and Division of Hematology, Ferrarotto Hospital-AOU Policlinic V. Emanuele, Catania
| | | | | | - Alessandra Iurlo
- UOC Onco-hematology, IRCCS Ca' Granda Foundation-Ospedale Maggiore Policlinico, Milan
| | | | - Carmen Fava
- Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano
| | | | | | - Federica Sorà
- Hematology, Catholic University of Sacred Heart of Rome
| | | | | | | | - Fausto Castagnetti
- Department of Hematology and Oncology "L. and A. Seràgnoli,", S. Orsola-Malpighi University Hospital, Bologna
| | | | - Sara Galimberti
- Department of Clinical and Experimental Medicine-Hematology, University of Pisa
| | | | | | - Patrizia Pregno
- Hematology, San Giovanni Battista Hospital and University, Turin
| | | | | | - Endri Mauro
- Department of Internal Medicine, General Hospital, Pordenone
| | - Nicola Sgherza
- Hematology, IRCCS, "Casa Sollievo della Sofferenza", San Giovanni Rotondo
| | | | | | | | | | - Paolo Vigneri
- Medical Oncology, AOU Policlinic V. Emanuele, University of Catania
| | - Massimo Breccia
- Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome
| | - Gianantonio Rosti
- Department of Hematology and Oncology "L. and A. Seràgnoli,", S. Orsola-Malpighi University Hospital, Bologna
| | - Giuliana Alimena
- Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome
| |
Collapse
|
20
|
Minervini CF, Cumbo C, Orsini P, Anelli L, Zagaria A, Impera L, Coccaro N, Brunetti C, Minervini A, Casieri P, Tota G, Russo Rossi A, Specchia G, Albano F. Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. Exp Mol Pathol 2017; 103:33-37. [DOI: 10.1016/j.yexmp.2017.06.007] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 05/22/2017] [Accepted: 06/25/2017] [Indexed: 01/11/2023]
|
21
|
Walker PA, Alesini PD, Alexandrova AS, Anania MP, Andreev NE, Andriyash I, Aschikhin A, Assmann RW, Audet T, Bacci A, Barna IF, Beaton A, Beck A, Beluze A, Bernhard A, Bielawski S, Bisesto FG, Boedewadt J, Brandi F, Bringer O, Brinkmann R, Bründermann E, Büscher M, Bussmann M, Bussolino GC, Chance A, Chanteloup JC, Chen M, Chiadroni E, Cianchi A, Clarke J, Cole J, Couprie ME, Croia M, Cros B, Dale J, Dattoli G, Delerue N, Delferriere O, Delinikolas P, Dias J, Dorda U, Ertel K, Ferran Pousa A, Ferrario M, Filippi F, Fils J, Fiorito R, Fonseca RA, Galimberti M, Gallo A, Garzella D, Gastinel P, Giove D, Giribono A, Gizzi LA, Grüner FJ, Habib AF, Haefner LC, Heinemann T, Hidding B, Holzer BJ, Hooker SM, Hosokai T, Irman A, Jaroszynski DA, Jaster-Merz S, Joshi C, Kaluza MC, Kando M, Karger OS, Karsch S, Khazanov E, Khikhlukha D, Knetsch A, Kocon D, Koester P, Kononenko O, Korn G, Kostyukov I, Labate L, Lechner C, Leemans WP, Lehrach A, Li FY, Li X, Libov V, Lifschitz A, Litvinenko V, Lu W, Maier AR, Malka V, Manahan GG, Mangles SPD, Marchetti B, Marocchino A, Martinez de la Ossa A, Martins JL, Massimo F, Mathieu F, Maynard G, Mehrling TJ, Molodozhentsev AY, Mosnier A, Mostacci A, Mueller AS, Najmudin Z, Nghiem PAP, Nguyen F, Niknejadi P, Osterhoff J, Papadopoulos D, Patrizi B, Pattathil R, Petrillo V, Pocsai MA, Poder K, Pompili R, Pribyl L, Pugacheva D, Romeo S, Rossi AR, Roussel E, Sahai AA, Scherkl P, Schramm U, Schroeder CB, Schwindling J, Scifo J, Serafini L, Sheng ZM, Silva LO, Silva T, Simon C, Sinha U, Specka A, Streeter MJV, Svystun EN, Symes D, Szwaj C, Tauscher G, Thomas AGR, Thompson N, Toci G, Tomassini P, Vaccarezza C, Vannini M, Vieira JM, Villa F, Wahlström CG, Walczak R, Weikum MK, Welsch CP, Wiemann C, Wolfenden J, Xia G, Yabashi M, Yu L, Zhu J, Zigler A. Horizon 2020 EuPRAXIA design study. ACTA ACUST UNITED AC 2017. [DOI: 10.1088/1742-6596/874/1/012029] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
22
|
Nirchio M, Oliveira C, Siccha-Ramirez ZR, Sene VF, Sánchez-Romero OR, Ehemann NR, Milana V, Rossi AR, Sola L. Cryptic Caribbean species of Scorpaena (Actinopterygii: Scorpaeniformes) suggested by cytogenetic and molecular data. J Fish Biol 2016; 89:1947-1957. [PMID: 27488622 DOI: 10.1111/jfb.13089] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 06/15/2016] [Indexed: 06/06/2023]
Abstract
Cytogenetic and molecular analyses enabled identification of two cytotypes among individuals of the spotted scorpion fish Scorpaena plumieri from Margarita Island, Venezuela. Cytotype 1 was characterized by 48 subtelo-acrocentric chromosomes and fundamental number (number of chromosome arms; FN) equalled 48, while cytotype 2 was characterized by two metacentric and 46 subtelo-acrocentric chromosomes and FN was 50. These cytotypes also differed in the location of the ribosomal gene clusters and in the distribution of the constitutive heterochromatin. Moreover, fish from the cytotypes 1 and 2 were found to belong to distinct mitochondrial lineages. The presence of two S. plumieri cytotypes from two lineages separated by high genetic distance suggests that they correspond to sympatric cryptic species.
Collapse
Affiliation(s)
- M Nirchio
- Escuela de Ciencias Aplicadas del Mar, Universidad de Oriente, Isla de Margarita, Venezuela
- Universidad Técnica de Machala, Ecuador
| | - C Oliveira
- Departamento de Morfologia, Instituto de Biociências Universidade Estadual Paulista, São Paulo, Brazil
| | - Z R Siccha-Ramirez
- Departamento de Morfologia, Instituto de Biociências Universidade Estadual Paulista, São Paulo, Brazil
| | - V F Sene
- Departamento de Morfologia, Instituto de Biociências Universidade Estadual Paulista, São Paulo, Brazil
| | | | - N R Ehemann
- Escuela de Ciencias Aplicadas del Mar, Universidad de Oriente, Isla de Margarita, Venezuela
| | - V Milana
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza - Università di Roma, Italy.
| | - A R Rossi
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza - Università di Roma, Italy
| | - L Sola
- Dipartimento di Biologia e Biotecnologie "C. Darwin", Sapienza - Università di Roma, Italy
| |
Collapse
|
23
|
Russo Rossi A. Nilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8. CMI 2015. [DOI: 10.7175/cmi.v4i5s.1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In this article is presented the case of a 30-year-old woman with chronic myeloid leukaemia (CML) treated with imatinib for 15 months, and then with nilotinib as second-line therapy. Two episodes of grade 3 neutropenia, the detection of the trisomy of chromosome 8 and the failed achievement of a major molecular response (MMolR) in 15 months led to the switch to nilotinib. With nilotinib the patient obtained the lack of the genetic anomaly in 3 months and a complete molecular response (CMolR) in 6 months, all confirmed at 9 months. No haematologic or extra-haematologic adverse events were detected with this second-line agent.
Collapse
|
24
|
Rossi AR. Deep and early molecular response induced by nilotinb in a newly diagnosed patient with chronic myeloid leukemia (CML). CMI 2015. [DOI: 10.7175/cmi.v7i1s.1144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We report a case of a patient with chronic myeloid leukemia diagnosed in January 2012 and treated with nilotinib 600 mg/die as first line therapy. Patient obtained a complete hematologic response (CHR) and improvement of splenomegaly in 2 weeks. In three months the patient obtained complete cytogenetic response (CCR) and an important transcript level reduction (less than 1%). According to the international recommendations, molecular analysis was performed every three months in a LABNET network laboratory. Treatment was never interrupted or reduced due to any adverse event. After 9 months patient achieved a major molecular response (MMR) and during evaluation a MR4 has been documented.
Collapse
|
25
|
Petralia A, Anania MP, Artioli M, Bacci A, Bellaveglia M, Carpanese M, Chiadroni E, Cianchi A, Ciocci F, Dattoli G, Di Giovenale D, Di Palma E, Di Pirro GP, Ferrario M, Giannessi L, Innocenti L, Mostacci A, Petrillo V, Pompili R, Rau JV, Ronsivalle C, Rossi AR, Sabia E, Shpakov V, Vaccarezza C, Villa F. Two-Color Radiation Generated in a Seeded Free-Electron Laser with Two Electron Beams. Phys Rev Lett 2015; 115:014801. [PMID: 26182099 DOI: 10.1103/physrevlett.115.014801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Indexed: 06/04/2023]
Abstract
We present the experimental evidence of the generation of coherent and statistically stable two-color free-electron laser radiation obtained by seeding an electron beam double peaked in energy with a laser pulse single spiked in frequency. The radiation presents two neat spectral lines, with time delay, frequency separation, and relative intensity that can be accurately controlled. The analysis of the emitted radiation shows a temporal coherence and a shot-to-shot regularity in frequency significantly enhanced with respect to the self-amplified spontaneous emission.
Collapse
Affiliation(s)
- A Petralia
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - M P Anania
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - M Artioli
- ENEA Centro Ricerche Bologna, Via Martiri Monte Sole 4, 40129 Bologna, Italy
| | - A Bacci
- INFN-Sezione di Milano, Via Celoria 16, 20133 Milano, Italy
| | - M Bellaveglia
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - M Carpanese
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - E Chiadroni
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - A Cianchi
- Università Tor Vergata di Roma, Via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - F Ciocci
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - G Dattoli
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - D Di Giovenale
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - E Di Palma
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - G P Di Pirro
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - M Ferrario
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - L Giannessi
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - L Innocenti
- Università Tor Vergata di Roma, Via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - A Mostacci
- Università La Sapienza di Roma, Via Antonio Scarpa 24, 00133 Roma, Italy
| | - V Petrillo
- INFN-Sezione di Milano, Via Celoria 16, 20133 Milano, Italy
- Università degli Studi di Milano, Via Celoria 16, 20133 Milano, Italy
| | - R Pompili
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - J V Rau
- ISM-CNR, Via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - C Ronsivalle
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - A R Rossi
- INFN-Sezione di Milano, Via Celoria 16, 20133 Milano, Italy
| | - E Sabia
- ENEA Centro Ricerche Frascati, Via Enrico Fermi 45, IT 00044 Frascati, Roma, Italy
| | - V Shpakov
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - C Vaccarezza
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| | - F Villa
- INFN Laboratori Nazionali di Frascati, Via Enrico Fermi 44, 00044 Frascati, Roma, Italy
| |
Collapse
|
26
|
Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica 2015; 100:1146-50. [PMID: 26113419 DOI: 10.3324/haematol.2015.129221] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Accepted: 06/23/2015] [Indexed: 12/24/2022] Open
Abstract
Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib versus imatinib (ENESTnd). Apart from this registration study, very few data are currently available on first-line nilotinib treatment. We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with chronic-phase chronic myeloid leukemia. Six-year overall survival and progression-free survival rates were 96%, with one death after progression to blast phase. At 6 years, 75% of the patients were still on nilotinib. The cumulative incidence of major molecular response was 98%; only one patient had a confirmed loss of major molecular response. The cumulative incidence of deep molecular response (MR 4.0) was 76%. Deep molecular response was stable (≥ 2 years) in 34% of these patients. Cardiovascular adverse events, mainly due to arterial thrombosis, occurred in 11/73 patients (15%), after 24 to 76 months of therapy. They were more frequent in elderly patients, and in those with baseline cardiovascular risk factors. None was fatal, although there was a relevant morbidity. This is the study with the longest follow-up of a high dose of nilotinib (400 mg twice daily): it highlights the high efficacy and the cardiovascular toxicity of the drug (CTG.NCT.00481052).
Collapse
Affiliation(s)
- Gabriele Gugliotta
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | - Fausto Castagnetti
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | | | - Luciano Levato
- Hematology Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy
| | - Mariella D'Adda
- Hematology Unit, "Spedali Civili" Hospital, Brescia, Ravenna, Italy
| | - Fabio Stagno
- Chair of Hematology, University of Catania, Ravenna, Italy
| | | | - Marzia Salvucci
- Hematology Unit, "S. Maria delle Croci" Hospital, Ravenna, Italy
| | - Carmen Fava
- Chair of Hematology, Department of Clinical and Biological Sciences, "S. Luigi Gonzaga" University Hospital, University of Torino, Orbassano, Italy
| | - Bruno Martino
- Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
| | - Michele Cedrone
- Hematology Unit, "S. Giovanni Addolorata" Hospital, Roma, Italy
| | - Monica Bocchia
- Chair of Hematology, "S. Maria alle Scotte" Hospital, University of Siena, Piacenza, Italy
| | - Elena Trabacchi
- Hematology Unit, "Guglielmo da Saliceto" Hospital, Piacenza, Italy
| | - Francesco Cavazzini
- Chair of Hematology, "S. Anna" University Hospital, University of Ferrara, Cagliari, Italy
| | - Emilio Usala
- Hematology Unit, "A. Businco" Hospital, Cagliari, Italy
| | | | - Maria Teresa Bochicchio
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | - Simona Soverini
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | | | - Michele Cavo
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | - Fabrizio Pane
- Chair of Hematology, Department of Biochemistry and Medical Biotechnologies, "Federico II" University, Napoli, Italy
| | - Giovanni Martinelli
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | - Giuseppe Saglio
- Chair of Hematology, Department of Clinical and Biological Sciences, "S. Luigi Gonzaga" University Hospital, University of Torino, Orbassano, Italy
| | - Michele Baccarani
- Department of Hematology and Oncology "L. and A. Seràgnoli", University of Bologna, Italy
| | - Gianantonio Rosti
- Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, "S. Orsola-Malpighi" University Hospital, University of Bologna, Roma, Italy
| | | |
Collapse
|
27
|
Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res 2014; 38:1173-6. [PMID: 25047978 DOI: 10.1016/j.leukres.2014.06.020] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Revised: 06/15/2014] [Accepted: 06/28/2014] [Indexed: 11/28/2022]
Abstract
We applied Charlson comorbidity index (CCI) stratification on a large cohort of chronic myeloid leukemia (CML) very elderly patients (>75 years) treated with imatinib, in order to observe the impact of concomitant diseases on both compliance and outcome. One hundred and eighty-one patients were recruited by 21 Italian centers. There were 95 males and 86 females, median age 78.6 years (range 75-93.6). According to Sokal score, 106 patients were classified as intermediate risk and 55 as high risk (not available in 20 patients). According to CCI stratification, 71 patients had score 0 and 110 a score ≥ 1. Imatinib standard dose was reduced at start of therapy (200-300 mg/day) in 68 patients independently from the evaluation of baseline comorbidities, but based only on physician judgement: 43.6% of these patients had score 0 compared to 34% of patients who had score ≥ 1. Significant differences were found in terms of subsequent dose reduction (39% of patients with score 0 compared to 53% of patients with score ≥ 1) and in terms of drug discontinuation due to toxicity (35% of patients with score 0 vs 65% of patients with score ≥ 1). We did not find significant differences as regards occurrence of hematologic side effects, probably as a consequence of the initial dose reduction: 39% of patients with score 0 experienced grade 3/4 hematologic toxicity (most commonly anemia) compared to 42% of patients with score ≥ 1. Independently from the initial dose, comorbidities again did not have an impact on development of grade 3/4 non-hematologic side effects (most commonly skin rash, muscle cramps and fluid retention): 62% of patients with score 0 compared to 52.5% of patients with score ≥ 1. Notwithstanding the reduced dose and the weight of comorbidities we did not find significant differences but only a trend in terms of efficacy: 66% of patients with score 0 achieved a CCyR compared to 54% of patients with score ≥ 1. Comorbidities appeared to have an impact on median OS (40.8 months for patients with score 0 vs 20.16 months for patients with score ≥ 1) on EFS and on non-CML death rate. Our results suggest that treatment of very elderly CML patients might be influenced by personal physician perception: evaluation at baseline of comorbidities according to CCI should improve initial decision-making in this subset of patients.
Collapse
Affiliation(s)
- Massimo Breccia
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza", Via Benevento 6, Roma 00161, Italy.
| | | | - Roberto Latagliata
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza", Via Benevento 6, Roma 00161, Italy
| | | | | | | | | | | | | | | | | | - Elena Crisà
- Ematologia, Università di Torino, Torino, Italy
| | - Pellegrino Musto
- Dipartimento Onco-Ematologico, IRCCS-CROB, Rionero in Vulture, Italy
| | | | | | | | - Alessandra Iurlo
- UOC Oncoematologia, Fondazione IRCSS Cà Granda Policlinico Milano, Milan, Italy
| | - Sabina Russo
- Ematologia, Università di Messina, Messina, Italy
| | | | | | | | - Mauro Endri
- Ematologia, Centro Trapianti Cremona, Cremona, Italy
| | | | - Matteo Molica
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza", Via Benevento 6, Roma 00161, Italy
| | | | | | - Federica Sorà
- Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Sergio Storti
- Onco-Ematologia, Università Cattolica Giovanni Paolo II, Campobasso, Italy
| | | | | | | | - Simona Sica
- Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy
| | | | | | | | - Giuliana Alimena
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza", Via Benevento 6, Roma 00161, Italy
| |
Collapse
|
28
|
Petrillo V, Anania MP, Artioli M, Bacci A, Bellaveglia M, Chiadroni E, Cianchi A, Ciocci F, Dattoli G, Di Giovenale D, Di Pirro G, Ferrario M, Gatti G, Giannessi L, Mostacci A, Musumeci P, Petralia A, Pompili R, Quattromini M, Rau JV, Ronsivalle C, Rossi AR, Sabia E, Vaccarezza C, Villa F. Observation of time-domain modulation of free-electron-laser pulses by multipeaked electron-energy spectrum. Phys Rev Lett 2013; 111:114802. [PMID: 24074094 DOI: 10.1103/physrevlett.111.114802] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Indexed: 06/02/2023]
Abstract
We present the experimental demonstration of a new scheme for the generation of ultrashort pulse trains based on free-electron-laser (FEL) emission from a multipeaked electron energy distribution. Two electron beamlets with energy difference larger than the FEL parameter ρ have been generated by illuminating the cathode with two ps-spaced laser pulses, followed by a rotation of the longitudinal phase space by velocity bunching in the linac. The resulting self-amplified spontaneous emission FEL radiation, measured through frequency-resolved optical gating diagnostics, reveals a double-peaked spectrum and a temporally modulated pulse structure.
Collapse
Affiliation(s)
- V Petrillo
- INFN-Milano and Università di Milano, Via Celoria, 16 20133 Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Albano F, Zagaria A, Anelli L, Coccaro N, Impera L, Minervini CF, Minervini A, Rossi AR, Tota G, Casieri P, Specchia G. Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation. Mol Cancer 2013; 12:36. [PMID: 23642027 PMCID: PMC3658885 DOI: 10.1186/1476-4598-12-36] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Accepted: 04/29/2013] [Indexed: 01/11/2023] Open
Abstract
Background The t(9;22)(q34;q11) generating the BCR/ABL1 fusion gene represents the cytogenetic hallmark of chronic myeloid leukemia (CML). About 5–10% of CML cases show variant translocations with the involvement of other chromosomes in addition to chromosomes 9 and 22. The molecular bases of biological differences between CML patients with classic and variant t(9;22) have never been clarified. Findings In this study, we performed gene expression microarray analysis to compare CML patients bearing variant rearrangements and those with classic t(9;22)(q34;q11). We identified 59 differentially expressed genes significantly associated with the two analyzed groups. The role of specific candidate genes such as TRIB1 (tribbles homolog 1), PTK2B (protein tyrosine kinase 2 beta), and C5AR1 (complement component 5a receptor 1) is discussed. Conclusions Our results reveal that in CML cases with variant t(9;22) there is an enhancement of the MAPK pathway deregulation and show that kinases are a common target of molecular alterations in hematological disorders.
Collapse
Affiliation(s)
- Francesco Albano
- Department of Emergency and Organ Transplantation-Hematology Section, University of Bari, Bari, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Sola L, Marzovillo M, Rossi AR, Gornung E, Bressanello S, Turner BJ. Cytogenetic analysis of a self-fertilizing fish, Rivulus marmoratus: remarkable chromosomal constancy over a vast geographic range. Genome 2012; 40:945-9. [PMID: 18464880 DOI: 10.1139/g97-121] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The aplocheiloid killifish Rivulus marmoratus is the only known self-fertilizing hermaphroditic vertebrate. Most natural populations consist almost entirely of hermaphrodites and comprise arrays of homozygous clones. However, in almost all populations thus far studied, clonal variation, as detected with molecular techniques, is very high. A karyological survey was carried out on specimens from Brazil, the Bahamas, Belize, and Florida (4 locales) by C-banding, silver staining, and fluorescent staining. The chromosome complement of R. marmoratus is surprisingly uniform over its vast geographic range, in terms of both chromosome number and morphology, heterochromatin distribution and composition, and nucleolar organizer region (NOR) distribution. The short arms of chromosome pair 15, where NORs are located, showed the only variation detected in this study: those of pattern A were consistently shorter than those of pattern B; moreover, the latter show positive heteropycnosis with Giemsa staining. The present data demonstrate that chromosomal variation is not a significant part of the clonal divergence in this species, even though its breeding system, by forming homozygotes for new rearrangements almost immediately, should make that variation easier to detect. The high chromosomal homogeneity is discussed in the light of the peculiar natural history of the species.
Collapse
|
31
|
Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 2012; 107:904-9. [PMID: 22871884 PMCID: PMC3464760 DOI: 10.1038/bjc.2012.348] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was to investigate patient-reported personal factors associated with adherence behaviour. Methods: Analysis was conducted on 413 CML patients receiving long-term therapy with imatinib. Adherence behaviour was measured with the Morisky Medication Adherence Scale and personal factors investigated included: quality of life, perceived social support, fatigue, symptom burden, psychological wellbeing and desire for additional information. Key socio-demographic and treatment-related factors were also taken into account. Univariate and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence to therapy. Results: In all, 53% of patients reported an optimal adherence behaviour. The final multivariate model retained the following variables as independent predictors of optimal adherence to therapy: desire for more information (ref. no), odds ratio (OR)=0.43 (95% confidence interval (CI), 0.29–0.66; P<0.001), social support (higher score representing greater support), OR=1.29 (95% CI, 1.11–1.49; P<0.001) and concomitant drug burden (ref. no), OR=1.82 (95% CI, 1.18–2.80; P=0.006). Conclusion: This study suggests that a higher level of social support, satisfaction with information received and concomitant drug burden are the main factors associated with greater adherence to long-term imatinib therapy.
Collapse
Affiliation(s)
- F Efficace
- Italian Group for Adult Hematologic Diseases, Data Center and Health Outcomes Research Unit, Via Benevento, 6, 00161 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Russo Rossi A, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica 2012; 98:399-403. [PMID: 22801965 DOI: 10.3324/haematol.2012.064337] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.
Collapse
|
33
|
Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F, Curci P, Rossi AR, Ricco A, Specchia G. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 18:887-93. [PMID: 22062803 DOI: 10.1016/j.bbmt.2011.10.039] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Accepted: 10/25/2011] [Indexed: 01/06/2023]
Abstract
Graft-versus-host disease (GVHD), mediated by mature T cells present in the donor graft, remains a major complication after allogeneic peripheral blood stem cell transplantation (PBSCT). Regulatory T cells (Tregs) (CD4(+)CD25(high)Foxp3(+)) are believed to maintain tolerance and to inhibit GVHD after allogeneic PBSCT (allo-PBSCT). In this study, we analyzed the graft CD3(+)/Tregs ratio (gCD3/Tregs R) and evaluated its impact on acute GVHD (aGVHD) and immunologic recovery after myeloablative allo-PBSCT. We analyzed 65 consecutive patients who underwent transplantation with unmanipulated peripheral blood stem cells from an HLA-identical related donor (n = 45) or an HLA-identical unrelated donor (n = 20). The median CD3(+) and Tregs doses administered were 256 × 10(6)/kg of body weight (range, 67-550 × 10(6)/kg) and 12 × 10(6)/kg (range, 2-21 × 10(6)/kg), respectively; the median gCD3/Tregs R value was 18 (range, 8-250). Patients were subdivided into a high gCD3/Tregs R (≥36) group (HR; n = 26) and a low gCD3/Tregs R (<36) group (LR; n = 39). The incidence of aGVHD (grade II-IV) was lower in the LR group compared with the HR group (8/39 [20%] versus 22/26 [84%]; P < .001). Median cytomegalovirus-specific CD8(+) T lymphocytes were significantly higher in the LR group than in the HR group at 1 month (2 cells/μL versus 0 cells/μL; P < .001), 2 months (6 cells/μL versus 1 cell/μL; P < .001), and 3 months (15 cells/μL versus 3 cells/μL; P < .001) months. Moreover, cytomegalovirus infection/disease was observed in 15% of patients in the LR group versus 69% of patients in the HR group (P < .001). At multivariate logistic regression, gCD3/Tregs R was correlated both with aGVHD (odds ratio, 2.50; 95% confidence interval, 1.30-4.50; P = .05) and with cytomegalovirus infection/disease (odds ratio, 2.35; 95% confidence interval, 0.9-5.00; P = .05). Taken together, our data may suggest that the balance in favor of graft Tregs content is able to mediate protective effects against aGVHD and to maintain an optimal microenviroment for the reconstitution of functional immunity.
Collapse
Affiliation(s)
- Domenico Pastore
- Hematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011; 96:1457-61. [PMID: 21685471 DOI: 10.3324/haematol.2011.041251] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data. DESIGN AND METHODS We retrospectively evaluated the Charlson index and adult comorbidity evaluation-27 score in a cohort of 125 elderly (> 60 years) patients with chronic phase chronic myeloid leukemia who received dasatinib after showing resistance or intolerance to imatinib with the aim of establishing associations between comorbidities and the development of pleural effusions or compliance with the drug treatment. RESULTS We found a significant association between the Charlson index as well as the adult comorbidity evaluation-27 score and the rate of drug reduction or suspension: with regards to the Charlson index, 49% of score 0 patients had a dose reduction compared to 63% of patients with score 1, 74% of those with score 2 and 100% of patients with score 3-5 (P=0.03); with regards to the adult comorbidity evaluation-27 score, 45% of patients had score 0-1 and 69% of patients with score 2-3 had a dose reduction. Of the 65 patients with Charlson score 0, 29% had at least one suspension of treatment (79% for hematologic and 21% for non-hematologic toxicity), compared to 46% of patients with score 1 (37% for hematologic and 69% for non-hematologic toxicity), 58% of patients with score 2 (36% for hematologic and 64% for non-hematologic toxicity) and 100% of patients with score 3 or 4 (all patients for both types of toxicity). High adult comorbidity index-27 scores identified patients at high risk of grade 3/4 hematologic toxicity. Forty-one patients (32.8%) experienced pleural effusion during treatment: the highest scores for both indices were associated with an increased risk of pleural effusions. CONCLUSIONS In elderly patients with chronic myeloid leukemia treated with dasatinib, the rate of drug reduction or suspension and the incidence of pleural effusions seem to be associated with the presence of comorbidities: stratification according to the Charlson index and adult comorbidity evaluation-27 score before dasatinib therapy may enable the identification of patients at risk of major toxicities.
Collapse
Affiliation(s)
- Massimo Breccia
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G. Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. Am J Hematol 2011; 86:523-5. [PMID: 21594891 DOI: 10.1002/ajh.22020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Massimo Breccia
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Giannessi L, Bacci A, Bellaveglia M, Briquez F, Castellano M, Chiadroni E, Cianchi A, Ciocci F, Couprie ME, Cultrera L, Dattoli G, Filippetto D, Del Franco M, Di Pirro G, Ferrario M, Ficcadenti L, Frassetto F, Gallo A, Gatti G, Labat M, Marcus G, Moreno M, Mostacci A, Pace E, Petralia A, Petrillo V, Poletto L, Quattromini M, Rau JV, Ronsivalle C, Rosenzweig J, Rossi AR, Rossi Albertini V, Sabia E, Serluca M, Spampinati S, Spassovsky I, Spataro B, Surrenti V, Vaccarezza C, Vicario C. Self-amplified spontaneous emission free-electron laser with an energy-chirped electron beam and undulator tapering. Phys Rev Lett 2011; 106:144801. [PMID: 21561195 DOI: 10.1103/physrevlett.106.144801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Indexed: 05/30/2023]
Abstract
We report the first experimental implementation of a method based on simultaneous use of an energy chirp in the electron beam and a tapered undulator, for the generation of ultrashort pulses in a self-amplified spontaneous emission mode free-electron laser (SASE FEL). The experiment, performed at the SPARC FEL test facility, demonstrates the possibility of compensating the nominally detrimental effect of the chirp by a proper taper of the undulator gaps. An increase of more than 1 order of magnitude in the pulse energy is observed in comparison to the untapered case, accompanied by FEL spectra where the typical SASE spiking is suppressed.
Collapse
Affiliation(s)
- L Giannessi
- ENEA C.R. Frascati, Via E. Fermi,45 00044 Frascati (RM), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer 2010; 9:120. [PMID: 20500819 PMCID: PMC2887383 DOI: 10.1186/1476-4598-9-120] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2010] [Accepted: 05/25/2010] [Indexed: 12/12/2022] Open
Abstract
Background The t(9;22)(q34;q11), generating the Philadelphia (Ph) chromosome, is found in more than 90% of patients with chronic myeloid leukemia (CML). As a result of the translocation, the 3' portion of the ABL1 oncogene is transposed from 9q34 to the 5' portion of the BCR gene on chromosome 22 to form the BCR/ABL1 fusion gene. At diagnosis, in 5-10% of CML patients the Ph chromosome is derived from variant translocations other than the standard t(9;22). Results We report a molecular cytogenetic study of 452 consecutive CML patients at diagnosis, that revealed 50 cases identifying three main subgroups: i) cases with variant chromosomal rearrangements other than the classic t(9;22)(q34;q11) (9.5%); ii) cases with cryptic insertions of ABL1 into BCR, or vice versa (1.3%); iii) cases bearing additional chromosomal rearrangements concomitant to the t(9;22) (1.1%). For each cytogenetic group, the mechanism at the basis of the rearrangement is discussed. All breakpoints on other chromosomes involved in variant t(9;22) and in additional rearrangements have been characterized for the first time by Fluorescence In Situ Hybridization (FISH) experiments and bioinformatic analyses. This study revealed a high content of Alu repeats, genes density, GC frequency, and miRNAs in the great majority of the analyzed breakpoints. Conclusions Taken together with literature data about CML with variant t(9;22), our findings identified several new cytogenetic breakpoints as hotspots for recombination, demonstrating that the involvement of chromosomes other than 9 and 22 is not a random event but could depend on specific genomic features. The presence of several genes and/or miRNAs at the identified breakpoints suggests their potential involvement in the CML pathogenesis.
Collapse
|
38
|
Ferrario M, Alesini D, Bacci A, Bellaveglia M, Boni R, Boscolo M, Castellano M, Chiadroni E, Cianchi A, Cultrera L, Di Pirro G, Ficcadenti L, Filippetto D, Fusco V, Gallo A, Gatti G, Giannessi L, Labat M, Marchetti B, Marrelli C, Migliorati M, Mostacci A, Pace E, Palumbo L, Quattromini M, Ronsivalle C, Rossi AR, Rosenzweig J, Serafini L, Serluca M, Spataro B, Vaccarezza C, Vicario C. Experimental demonstration of emittance compensation with velocity bunching. Phys Rev Lett 2010; 104:054801. [PMID: 20366769 DOI: 10.1103/physrevlett.104.054801] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2009] [Indexed: 05/29/2023]
Abstract
In this Letter we report the first experiments aimed at the simultaneous demonstration of the emittance compensation process and velocity bunching in a high brightness electron source, the SPARC photoinjector in INFN-LNF. While a maximum compression ratio up to a factor 14 has been observed, in a particular case of interest a compression factor of 3, yielding a slice current of 120 A with less than 2 microm slice emittance, has been measured. This technique may be crucial in achieving high brightness beams in photoinjectors aiming at optimized performance of short wavelength single-pass free electron lasers or other advanced applications in laser-plasma accelerators.
Collapse
Affiliation(s)
- M Ferrario
- INFN-LNF, Via Enrico Fermi, 40-00044 Frascati, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martin-Jimenez P, Maria Hernandez J, Rigolin GM, Cuneo A. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008; 142:529-37. [DOI: 10.1111/j.1365-2141.2008.07227.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Mostacci A, Bacci A, Boscolo M, Chiadroni E, Cianchi A, Filippetto D, Migliorati M, Musumeci P, Ronsivalle C, Rossi AR. Analysis methodology of movable emittance-meter measurements for low energy electron beams. Rev Sci Instrum 2008; 79:013303. [PMID: 18248027 DOI: 10.1063/1.2835715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The design of photoinjectors for modern free electron laser linac relies heavily on particular beam behavior in the few meters after the gun. To experimentally characterize it a movable emittance meter was proposed and built [L. Catani et al., Rev. Sci. Instrum. 77, 093301 (2006)] based on the beam slicing technique. This paper addresses all the aspects of analysis of the data acquired with the emittance meter and common to any slit based emittance measurement for low energy beams.
Collapse
Affiliation(s)
- A Mostacci
- La Sapienza Università di Roma, 00161 Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ferrario M, Alesini D, Bacci A, Bellaveglia M, Boni R, Boscolo M, Castellano M, Catani L, Chiadroni E, Cialdi S, Cianchi A, Clozza A, Cultrera L, Di Pirro G, Drago A, Esposito A, Ficcadenti L, Filippetto D, Fusco V, Gallo A, Gatti G, Ghigo A, Giannessi L, Ligi C, Mattioli M, Migliorati M, Mostacci A, Musumeci P, Pace E, Palumbo L, Pellegrino L, Petrarca M, Quattromini M, Ricci R, Ronsivalle C, Rosenzweig J, Rossi AR, Sanelli C, Serafini L, Serio M, Sgamma F, Spataro B, Tazzioli F, Tomassini S, Vaccarezza C, Vescovi M, Vicario C. Direct measurement of the double emittance minimum in the beam dynamics of the sparc high-brightness photoinjector. Phys Rev Lett 2007; 99:234801. [PMID: 18233375 DOI: 10.1103/physrevlett.99.234801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2007] [Indexed: 05/25/2023]
Abstract
In this Letter we report the first experimental observation of the double emittance minimum effect in the beam dynamics of high-brightness electron beam generation by photoinjectors; this effect, as predicted by the theory, is crucial in achieving minimum emittance in photoinjectors aiming at producing electron beams for short wavelength single-pass free electron lasers. The experiment described in this Letter was performed at the SPARC photoinjector site, during the first stage of commissioning of the SPARC project. The experiment was made possible by a newly conceived device, called an emittance meter, which allows a detailed and unprecedented study of the emittance compensation process as the beam propagates along the beam pipe.
Collapse
Affiliation(s)
- M Ferrario
- INFN-LNF, Via E. Fermi, 40-00044 Frascati, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Rossi AR, Gornung E, Sola L, Nirchio M. Comparative molecular cytogenetic analysis of two congeneric species, Mugil curema and M. liza (Pisces, Mugiliformes), characterized by significant karyotype diversity. Genetica 2005; 125:27-32. [PMID: 16175452 DOI: 10.1007/s10709-005-2668-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Accepted: 02/04/2005] [Indexed: 11/30/2022]
Abstract
Two congeneric mullet species, Mugil liza and M. curema, respectively with an all-uniarmed and an all-biarmed karyotype, were cytogenetically studied by base-specific fluorochrome staining and FISH-mapping of 45S and 5S ribosomal RNA genes (rDNA) and the (TTAGGG)(n) telomeric repeats. Whereas 45S rDNA sites might be homeologus in the two species, 5S rDNA sites are not, as they are localized on chromosome arms of different size. In both species, the (TTAGGG)(n) telomeric probe hybridized to natural telomeres and was found scattered along the NORs. In metacentric chromosomes of M. curema, no pericentromeric signals of the telomeric probe were detected. Data are discussed in relation to the karyotype evolution in Mugilidae and to the mechanisms and the evolutionary implications of Robertsonian rearrangements in M. curema.
Collapse
Affiliation(s)
- A R Rossi
- Department of Animal and Human Biology, University of Rome I "La Sapienza", via A. Borelli 50, 00161 Rome, Italy
| | | | | | | |
Collapse
|
43
|
Della Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, Fraulini C, Russo Rossi A, Riccardi A, Castoldi G. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005; 68:276-84. [PMID: 16015045 DOI: 10.1159/000086784] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2004] [Accepted: 09/12/2004] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Dendritic cells (DC) are central to the development of immune system responses. In a cohort of 54 patients affected by colorectal cancer, we prospectively investigated the number of peripheral blood (PB) DC type 1 (DC1) and type 2 (DC2) and correlated their counts and functionality to the stage of the disease and to vascular endothelial growth factor (VEGF) levels. RESULTS At diagnosis, compared with healthy controls, patients presented reduced PBDC1 and PBDC2 numbers (p < 0.001). Moreover, in cancer patients, PBDC showed low levels of DC-associated antigens (HLA DR, p = 0.004; CD11c, p < 0.001; CD83, p = 0.01; CD86, p = 0.007 and Mannose receptor, p = 0.029), an upregulation of CXCR4 (p = 0.017) and a reduced T cell stimulation capability (p < 0.001). DC1 and DC2 loss was higher in stage D versus stage ABC patients (p = 0.003 and p = 0.002, respectively); surgery and chemotherapy appeared to attenuate a DC defect, although the restoration of normal PBDC levels is completed only at 6 and 12 months after diagnosis, respectively. In this series of patients, PBDC1 and PBDC2 numbers inversely correlated with VEGF serum levels (p < 0.001), suggesting a possible effect of this cytokine on DC compartment. In culture, the exposure of monocyte-derived DC to VEGF produced a dramatic alteration of DC differentiation by (1) induction of apoptosis, (2) alteration of DC immunophenotypic profile and (3) increased CXCR4 expression. Exposure to anti-VEGF blocking antibodies reversed VEGF inhibitory effects in all cases. CONCLUSIONS These findings suggest that in colorectal cancer patients there is a numerical and functional impairment of PBDC compartment possibly related to the stage of the disease and to VEGF levels.
Collapse
Affiliation(s)
- Matteo Della Porta
- Section of Hematology, Department of Biomedical Sciences, University of Ferrara, Ferrara, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Sola L, Rossi AR, Annesi F, Gornung E. Cytogenetic studies in Sparus auratus (Pisces, Perciformes): molecular organization of 5S rDNA and chromosomal mapping of 5S and 45S ribosomal genes and of telomeric repeats. Hereditas 2004; 139:232-6. [PMID: 15061807 DOI: 10.1111/j.1601-5223.2003.01814.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- L Sola
- Department of Animal and Human Biology, University of Rome I "La Sapienza", Via A. Borelli 50, IT-00161 Rome, Italy. E-mail:
| | | | | | | |
Collapse
|
45
|
Rigolin GM, Porta MD, Ciccone M, Bugli AM, Bragotti LZ, Mauro E, Fraulini C, Rossi AR, Bardi A, Cuneo A, Castoldi G. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34+
cells. Br J Haematol 2004; 126:501-7. [PMID: 15287942 DOI: 10.1111/j.1365-2141.2004.05086.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The in vivo effect of recombinant human erythropoietin (rHuEpo) and granulocyte colony-stimulating factor (G-CSF) combined treatment on CD34(+) cells was evaluated by fluorescence in situ hybridization (FISH) in 13 myelodysplastic syndrome (MDS) patients with known cytogenetic abnormalities. After treatment, responsive patients presented a significantly lower proportion of FISH abnormal CD34(+) cells than before treatment (P = 0.003), and in comparison with unresponsive cases (P = 0.007). Response to treatment was associated with a reduced degree of apoptosis in CD34(+) cells (P = 0.021): however, no difference in telomere length was observed in responsive patients after growth factor administration. Although the number of patients analysed was relatively small, the present data suggest that, in MDS patients, response to rHuEpo and G-CSF may be related to the proliferation of karyotypically normal but potentially defective CD34(+) progenitor cells.
Collapse
Affiliation(s)
- Gian Matteo Rigolin
- Section of Haematology, Department of Biomedical Sciences, University of Ferrara, Ferrara, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gornung E, Mannarelli ME, Rossi AR, Sola L. Chromosomal evolution in Mugilidae (Pisces, Mugiliformes): FISH mapping of the (TTAGGG) telomeric repeat in the six Mediterranean mullets. Hereditas 2004; 140:158-9. [PMID: 15061795 DOI: 10.1111/j.1601-5223.2004.01784.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- E Gornung
- Department of Animal and Human Biology, University of Roma I La Sapienza, Italy
| | | | | | | |
Collapse
|
47
|
Abstract
Selective or restrictive access policies operate for breast reduction, despite proven benefits. The rationale for these policies, in particular the requirement of psychiatric assessment prior to a plastic surgical consultation, as an aid to patient selection by the health commission, was examined in 57 general practice referrals to a plastic surgical unit. In 22 cases, these policies deterred the patient or GP from pursuing the referral further. Sixteen cases were funded by the health commission directly, 16 patients required psychiatric or orthopaedic referrals, and three patients were refused funding outright. The decision to fund, reject or refer to a non-plastic-surgical specialist was not statistically related to the patients' symptoms. Non-plastic-surgical assessment resulted in referral for a plastic surgical opinion in 15 of 16 patients. We conclude that these selective policies are unsatisfactory, since patient management is not related to symptoms and the use of non-plastic-surgical opinions by the health commission as an aid to rationing is of little benefit.
Collapse
Affiliation(s)
- N Horlock
- RAFT Institute for Plastic Surgery, Mount Vernon Hospital, Northwood, UK
| | | | | |
Collapse
|
48
|
Rossi AR, Gornung E, Crosetti D. Cytogenetic analysis of Liza ramada (Pisces, Perciformes) by different staining techniques and fluorescent in situ hybridization. Heredity (Edinb) 1997; 79 ( Pt 1):83-7. [PMID: 9253614 DOI: 10.1038/hdy.1997.125] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
A cytogenetic investigation was carried out on specimens of Liza ramada, a mugilid species common in the Mediterranean sea. The analysis of chromosomes was performed through Ag-staining, C-banding, chromomycin A3 and DAPI staining, and fluorescent in situ hybridization with ribosomal genes. The results obtained are discussed with respect to cytotaxonomic implications and to the features of NORs.
Collapse
Affiliation(s)
- A R Rossi
- Department of Animal and Human Biology, University of Rome, Italy
| | | | | |
Collapse
|
49
|
Rashleigh SP, Kusher DI, Endicott JN, Rossi AR, Djeu JY. Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996; 122:541-7. [PMID: 8615973 DOI: 10.1001/archotol.1996.01890170073014] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
OBJECTIVES To examine the capacity of interleukin-2 (IL-2) and interleukin-12 (IL-12) to modulate the cytolytic activity of peripheral blood mononuclear cells against squamous cell carcinoma, and to determine whether peripheral blood mononuclear cells from healthy donors respond differently to IL-12 than do peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma. DESIGN Case-comparison study of a consecutive sample of patients with head and neck squamous cell carcinoma who were scheduled to undergo surgical excision. PARTICIPANTS The study included 10 patients with stage III or IV carcinoma matched with 10 volunteer blood donors. INTERVENTION Isolated peripheral blood mononuclear cells from patients and volunteers were treated with IL-2, 10 U/mL and 100 U/mL; IL-12, 1 U/mL or 10 U/mL; or a combination of IL-2 and IL-12. RESULTS The combination of IL-2 and IL-12 consistently produced the greatest activation cytolysis than either cytokine alone at all concentrations tested. This increased activity against a squamous cell carcinoma cell line was seen in lymphocytes from volunteers and patients. CONCLUSION Our findings suggest a new treatment regimen for the patient with head and neck cancer that uses immunomodulation with a combination of cytokines.
Collapse
Affiliation(s)
- S P Rashleigh
- Division of Otolaryngology-Head and Neck Surgery, University of South Florida, School of Medicine, Tampa, USA
| | | | | | | | | |
Collapse
|
50
|
Rossbach HC, Sutcliffe MJ, Haag MM, Grana NH, Rossi AR, Barbosa JL. Fanconi anemia in brothers initially diagnosed with VACTERL association with hydrocephalus, and subsequently with Baller-Gerold syndrome. Am J Med Genet 1996; 61:65-7. [PMID: 8741921 DOI: 10.1002/(sici)1096-8628(19960102)61:1<65::aid-ajmg12>3.0.co;2-u] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Two brothers with presumed Baller-Gerold syndrome, one of whom was previously diagnosed with the association of vertebral, cardiac, renal, limb anomalies, anal atresia, tracheo-esophageal fistula (VACTERL) association with hydrocephalus, were evaluated for chromosome breakage because of severe thrombo cytopenia in one of them. Spontaneous and clastogen-induced breakage was markedly increased in both patients as compared to control individuals. Clinical manifestations and chromosome breakage, consistent with Fanconi anemia, in patients with a prior diagnosis of either Baller-Gerold syndrome, reported earlier in one other patient [Farrell et al., 1994: Am J Med Genet 50:98-99], or with VACTERL association with hydrocephalus, recently reported in 3 patients [Toriello et al., 1991: Proc Greenwood Genet Center 11:142; Porteus et al., 1992: Am J Med Genet 43:1032-1034], underline the clinical heterogeneity of Fanconi anemia and raise the question of whether these syndromes are distinct disorders or phenotypic variations of the same disease.
Collapse
Affiliation(s)
- H C Rossbach
- Division of Pediatric Hematology/Oncology, All Children's Hospital, University of South Florida, St. Petersburg 33701, USA
| | | | | | | | | | | |
Collapse
|